AstraZeneca PLC · LSE:AZN
AstraZeneca — Investor Presentation (2001)
7 slides from AstraZeneca's investor presentation, 2001
Slide 1: Key Events in December
A Tom McKillop Key Events in December b Omeprazole trial commences Dec 6 b Arimidex® adjuvant data (ATAC) Dec 10 b Iressa™ filings (US/J) end Dec b Casodex® EPC filing (US) end Dec A Closing remarks: Tom McKillop A
Slide 2: Key events - early 2002
Key events - early 2002 b Arimidex® adjuvant BC filing (EU/US) Q1 b Symbicort® COPD filing (EU) Q1 b Zomig® nasal spray filing (US) Q1 b Iressa™ combination filing (EU/US) Q2 b Iressa™ Ideal 2 trial data – ASCO May b Faslodex™ 2nd line BC launch (US) 1H A Business transformation challenge b Optimise
Slide 3: Optimise established franchises
Optimise established franchises b Respiratory portfolio ! US $518 m +41% ! Total $1471 m +15% b Beta-Blockers ! US $453 m +37% ! Total $1210 m +15% Note: All sales MAT Sep 01 Growth rate CER A Business transformation challenge b Optimise established franchises b Drive the growth products A Closing r
Slide 4: Drive the growth products
Drive the growth products Moving Annual Totals 2000 Arimidex® 1500 Zomig® $m Atacand® Casodex® 1000 Seroquel® 500 0 Q3 00 Q4 00 Q1 01 Q2 01 Q3 01 A Business transformation challenge b Optimise established franchises b Drive the growth products b Success with launch of new products A Closing remarks:
Slide 5: Nexium US Launch Success; Symbicort European launch success
Nexium® - US Launch Success 180,000 Nexium® 160,000 140,000 TRx 120,000 100,000 80,000 Protonix® 60,000 Aciphex® 40,000 20,000 0 Week 1 Week 3 Week 5 Week 7 Week 9 Week 11 Week 13 Week 15 Week 17 Week 19 Week 21 Week 23 Week 25 Week 27 Week 29 Week 31 Week 33 Week 35 Pre-Launch Pre-Launch Source: IM
Slide 6: Effecting the transformation
Business transformation challenge b Optimise established franchises b Drive the growth products b Success with launch of new products b On target to deliver development portfolio A Effecting the transformation 2000: First launches – Nexium®,Symbicort® 2001: Broad roll-out – Nexium®, Symbicort® Major
Slide 7: The best portfolio… in the best hands
The best portfolio… A ...in the best hands A Closing remarks: Tom McKillop A